Does Retatrutide Affect Female Fertility? Trials, PCOS and Pregnancy Endpoints
Compare retatrutide outcome lists with a liraglutide PCOS fertility trial, including endpoint checks and pregnancy-rate denominator calculations.
FormBlends Editorial Research · Updated 2026-10-03
Retatrutide is investigational and is not FDA-approved. FDA states that it cannot be used in compounding under federal law. FormBlends does not prescribe, compound or sell retatrutide.
The selected retatrutide trials do not establish whether it improves or reduces female fertility. They include women, but the weight results do not measure ovulation, ovarian reserve or a pregnancy rate. A small liraglutide study did measure pregnancies in women with PCOS undergoing fertility treatment. It answers a different question about a different drug.
Women in a trial versus a fertility result
| Study | Participants | Relevant measurement | Interpretation |
|---|---|---|---|
| Retatrutide phase 2 obesity trial | 338 adults | Weight change at 24 and 48 weeks | Weight loss is not a measured conception rate |
| Retatrutide TRIUMPH-2, 2026 | 1,152 adults with obesity and type 2 diabetes, including 554 women | Primary body-weight assessment at 80 weeks | Female enrollment does not establish a fertility endpoint |
| Salamun and colleagues, 2018 | 28 infertile women with obesity and PCOS | Pregnancy after a liraglutide-plus-metformin or metformin intervention | Direct reproductive measurement, but a different drug and selected population |
| Retatrutide oral-contraceptive study | 46 postmenopausal women | Blood concentration measurements of two pill ingredients | An absorption study is not an ovulation or pregnancy-prevention study |
Our check of the retatrutide outcome lists
We checked the primary and secondary registered outcome-measure fields for NCT04881760 and NCT05929079 on October 3, 2026. There are 14 and 16 entries, respectively. None names ovulation, ovarian reserve, anti-Mullerian hormone, conception, pregnancy or live birth as its outcome measure.
These are two selected efficacy-outcome lists, not every retatrutide record or every safety event. Repeated measurements at different times count as separate entries. The check shows why a weight result cannot answer this page's question: the relevant reproductive outcome would need to be measured separately.
What the liraglutide PCOS pilot actually found
The 28-person randomized, open-label study compared metformin alone with liraglutide plus metformin over 12 weeks. Ovarian stimulation began after a four-week medication-free period. Reported pregnancy rates per embryo transfer were 85.7% with the combination and 28.6% with metformin alone. Cumulative pregnancy rates over 12 months were 69.2% and 35.7%.
The embryo-transfer comparison is a 57.1 percentage-point difference: 85.7 minus 28.6. The cumulative comparison is a 33.5 percentage-point difference: 69.2 minus 35.7. These are two different denominators and time frames, so the numbers are not interchangeable. Neither figure is a retatrutide result.
The participants had infertility, obesity and PCOS, and the intervention combined two drugs before fertility treatment. It was not a trial of retatrutide, natural conception in an unselected population, or treatment during pregnancy. The abstract does not establish a live-birth rate. Its small sample and open-label design matter when interpreting the result.
A reproductive-claim comparison you can reuse
| Headline claim | Measurement needed | What cannot substitute |
|---|---|---|
| Improves ovulation | Measured ovulation with a specified method and comparator | Weight change alone |
| Improves ovarian reserve | Specified reserve measurements and interpretation | Regular periods alone |
| Increases pregnancy rate | Pregnancies divided by a defined participant, cycle or transfer denominator | A change in a hormone marker |
| Increases live births | Live births with a specified denominator and follow-up | Pregnancy rate alone |
The useful comparison is intervention plus population plus endpoint plus denominator. A study can be strong evidence for its own question and still leave the retatrutide fertility question unanswered.
Frequently asked questions
Does retatrutide improve fertility in women with PCOS?
The selected retatrutide trials do not establish that result. The pregnancy pilot used liraglutide plus metformin, so it cannot be relabeled as evidence that retatrutide treats infertility in PCOS.
Does a lack of fertility endpoints mean retatrutide causes infertility?
No. An outcome that was not measured does not supply evidence of either improvement or deterioration.
Does the birth-control absorption study answer the fertility question?
No. It enrolled postmenopausal women and specified pharmacokinetic measurements. Measuring pill ingredients in blood differs from measuring ovulation, conception or live birth.
The sources here do not establish retatrutide as an approved treatment for this population or condition. Eligibility for research is determined by the individual protocol, not by a website BMI calculator or a telehealth assessment. No personalized suitability or adjustment of other treatment can be inferred from this article.